Spots Global Cancer Trial Database for Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
Official Title: Evaluate the Safety and Immunogenicity of the 9-valent Human Papillomavirus Recombinant Vaccine (Hansenula Polymorpha) in Chinese Male Aged 9-45 Years: A Randomized, Blinded and Placebo-Controlled Phase I Study
Study ID: NCT05518201
Study Description
Brief Summary: To evaluate the safety and tolerability of the 9vHPV vaccine in Chinese healthy male aged 9 to 45 years.
Detailed Description:
Keywords
Eligibility
Minimum Age: 9 Years
Eligible Ages: CHILD, ADULT
Sex: MALE
Healthy Volunteers: Yes
Locations
Center for Disease Control and Prevention, Mianzhu, Sichuan, China
Contact Details
Name: Ting Huang
Affiliation: Sichuan Provincial Center for Disease Control and Prevention
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
